Table 1 Baseline demographics and disease characteristics
|  | Total baricitinib (N = 106) |
|---|---|
Age, years, mean (SD) | 55.1 (11.5) |
 < 65 years, n (%) | 82 (77) |
 ≥ 65 years, n (%) | 24 (23) |
Female, n (%) | 85 (80) |
Race, n (%) | |
 White | 89 (84) |
 Black/African American | 15 (14) |
 Asian | 1 (1) |
 Multiple or other | 1 (1) |
Duration of RA diagnosis, years, mean (SD) | 12.1 (9.3) |
MTX use, n (%) | |
 Without MTX | 12 (11) |
 MTX-treated | 94 (89) |
 Weekly dose (mg/week), mean (SD) | 18.2 (6.6) |
Current corticosteroid use, n (%) | 32 (30) |
 Daily dose (mg/day), mean (SD) | 6.2 (2.7) |
Weight, kg, mean (SD) | 87.6 (21.7) |
Swollen joint count, of 66, mean (SD) | 3.7 (4.7) |
Tender joint count, of 68, mean (SD) | 5.0 (9.0) |
hsCRP, mg/L, mean (SD) | 9.3 (15.2) |
HAQ-DI, mean (SD), (range 0–3) | 0.9 (0.6) |
DAS28-CRP, mean (SD) (range 2–10) | 2.9 (1.1) |
CDAI, mean (SD) | 8.9 (8.8) |
SDAI, mean (SD) | 9.9 (8.8) |
Physician’s global assessment of disease activity (0–100), mean (SD) | 14.2 (14.6) |